A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Mcgowan, Ian ^a,b   Hoesley, Craig ^c   Cranston, Ross D ^a   Andrew, Philip ^d   Janocko, Laura ^b   Dai, James Y ^e,f   Carballo Dieguez, Alex ^g   Ayudhya, Ratiya Kunjara Na ^b   Piper, Jeanna ^h   Hladik, Florian ^e,f   Mayer, Ken ⁱ  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d FAMILY HEALTH INTERNATIONAL   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ FENWAY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; CYTOKINE; GLYCEROL; HYDROXYETHYLCELLULOSE; MESSENGER RNA; MICROBICIDE; MTN 007; NONOXINOL 9; PLACEBO; PROTEIN; TENOFOVIR; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANALYTICAL PARAMETERS; ANUS PRURITUS; ARTICLE; CELLULITIS; COMPUTER ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEFECATION URGENCY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EPITHELIAL SLOUGHING; FEMALE; FLATULENCE; FLOW CYTOMETRY; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HEMORRHOID; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERACTIVE VOICE RESPONSE SYSTEM; INTESTINE POLYP; MAJOR DEPRESSION; MALE; MICROARRAY ANALYSIS; MUCOSAL DISEASE; PAINFUL DEFECATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PROCTALGIA; PROCTITIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RECTUM MICROFLORA; RECTUM MUCOSA; RECTUM POLYP; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT OUTCOME;

ADENINE; ADMINISTRATION, RECTAL; ADULT; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; FEMALE; GELS; HIV INFECTIONS; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPHOSPHONATES; RECTUM; TRANSCRIPTOME; YOUNG ADULT;

EID: 84875746052     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060147     Document Type: Article

References (25)

1. McGowan I, (2011) Rectal microbicides: can we make them and will people use them? AIDS Behav 15 (Suppl 1): S66-S71.
2. Chen SY, Gibson S, Weide D, McFarland W, (2003) Unprotected anal intercourse between potentially HIV-serodiscordant men who have sex with men, San Francisco. J Acquir Immune Defic Syndr 33: 166-170.
3. Gorbach PM, Manhart LE, Hess KL, Stoner BP, Martin DH, et al. (2009) Anal intercourse among young heterosexuals in three sexually transmitted disease clinics in the United States. Sex Transm Dis 36: 193-198.
4. Kalichman SC, Simbayi LC, Cain D, Jooste S, (2009) Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex Transm Infect 85: 411-415.
5. Lane T, Pettifor A, Pascoe S, Fiamma A, Rees H, (2006) Heterosexual anal intercourse increases risk of HIV infection among young South African men. AIDS 20: 123-125.
6. Baral S, Sifakis F, Cleghorn F, Beyrer C, (2007) Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000-2006: a systematic review. PLoS Med 4: e339.
7. Abdool KQ, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
8. Anton PA, Cranston RD, Kashuba A, Hendrix C, Bumpus NN, et al. (2012) RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Compared to Oral Tenofovir Disoproxil Fumarate. AIDS Res Hum Retroviruses 28: 1412-1421.
9. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, et al. (2010) In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE 5: e9310.
10. Dezzutti CS, Rohan LC, Wang L, Uranker K, Shetler C, et al. (2012) Reformulated tenofovir gel for use as a dual compartment microbicide. J Antimicrob Chemother 67: 2139-2142.
11. Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, et al. (2011) First Phase 1 Double-Blind, Placebo-Controlled, Randomized Rectal Microbicide Trial Using UC781 Gel with a Novel Index of Ex Vivo Efficacy. PLoS ONE 6: e23243.
12. Tabet SR, Surawicz C, Horton S, Paradise M, Coletti AS, et al. (1999) Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Infect 26: 564-571.
13. Fichorova RN, Tucker LD, Anderson DJ, (2001) The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 184: 418-428.
14. Moher D, Schulz KF, Altman D, (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285: 1987-1991.
15. Schulz KF, Altman DG, Moher D, (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7: e1000251.
16. Schwartz JL, Ballagh SA, Kwok C, Mauck CK, Weiner DH, et al. (2007) Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 75: 136-141.
17. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, et al. (2000) A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47: 404-409.
18. McGowan I, Elliott J, Cortina G, Tanner K, Siboliban C, et al. (2007) Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr 46: 417-425.
19. Gaya DR, Lyon TD, Duncan A, Neilly JB, Han S, et al. (2005) Faecal calprotectin in the assessment of Crohn's disease activity. QJM 98: 435-441.
20. Patton DL, Cosgrove Sweeney YT, Rabe LK, Hillier SL, (2002) Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis 29: 581-587.
21. Stoner KA, Rabe LK, Austin MN, Meyn LA, Hillier SL, (2008) Quantitative survival of aerobic and anaerobic microorganisms in Port-A-Cul and Copan transport systems. J Clin Microbiol 46: 2739-2744.
22. Rabe LK, Hillier SL, (2003) Optimization of media for detection of hydrogen peroxide production by Lactobacillus species. J Clin Microbiol 41: 3260-3264.
23. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 57(1): 289-300.
24. Patton DL, Sweeney YT, Paul KJ, (2009) A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model. Sex Transm Dis 36: 350-356.
25. Smithson JE, Campbell A, Andrews JM, Milton JD, Pigott R, et al. (1997) Altered expression of mucins throughout the colon in ulcerative colitis. Gut 40: 234-240.